Study Zeroes In On Post-Transplant Anemia
Anemia that occurs after renal transplantation is due to more than just impaired allograft function. Gender, creatinine clearance, and age also contribute to development of the condition.
Anemia that occurs after renal transplantation is due to more than just impaired allograft function. Gender, creatinine clearance, and age also contribute to development of the condition.
Long-term use of vitamin E-coated polysulfone membrane (VECM) dialysis filters may significantly improve hemoglobin levels and reduce requirements of erythropoietin (EPO), according to an Italian study.
Achieving high hemoglobin levels in patients with CKD anemia may confer no cardiovascular benefit and could even increase the risk of death and cardiac problems, according to two studies published in the New England Journal of Medicine (2006;355:2071-2084;2085-2098).
The recent publication of the CHOIR and CREATE studies in the New England Journal of Medicine questioning hemoglobin targets in dialysis patients have resulted in intense scrutiny of the relationship between Amgen, dialysis organizations, and physicians in the management of anemia.
Anemia in CKD patients is an important risk factor for progression to end-stage renal disease (ESRD).
Amgen Inc., of Thousand Oaks, Calif., has received an approvable letter from the FDA for Aranesp (darbepoetin alfa) for de novo once-every-two-week dosing and for once-monthly maintenance dosing for non-dialysis CKD patients with anemia.
Darbepoetin alfa administered once every two weeks (Q2W) safely and effectively treats anemia in hemodialysis patients without having to increase the dose, according to researchers in Portugal.
Amgen is launching its recently approved Aranesp (darbepoetin alfa) prefilled SureClick autoinjector for patients with anemia associated with CKD and chemotherapy-induced anemia.